资讯
10 小时
HealthDay on MSNMany Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple MyelomaIn a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a ...
Columnist Leigh Anne Nelson rethinks her MS medication, discovering a risk and navigating crucial treatment decisions with ...
2 天
TheHealthSite on MSNDengue And Chikungunya Cases Surge In Bengaluru, Children And Pregnant Women At RiskSurge in dengue and chikungunya cases peaks as monsoon season arrives. Protect yourself and especially children and pregnant women as they are more susceptible to mosquito-borne illness.
ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果